(NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial hypertension ...

Merck & Co. Inc. closed 27.25% short of its 52-week high of $134.63, which the company reached on June 25th.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...

Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Merck (MRK) announced that the board of directors has declared a quarterly dividend of 81c per share of the company’s common stock for the ...

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

In the most recent trading session, Merck (MRK) closed at $97.45, indicating a -0.5% shift from the previous trading day.

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

JESI, Italy-- (BUSINESS WIRE/AETOSWire): Diatech Pharmacogenetics announced an expansion of its collaboration with Merck ...